GlassScriptPhysician profile
Leah Lande
NPI 1164457602
$1,529.31
in general payments reported to CMS, 2019-2025
17 companies · $309 in 2025
The $309 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $31.83 · 2021: $230 · 2022: $209 · 2023: $204 · 2024: $383 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $630.89 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $194.91 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $141.94 | 2019-2025 | Fasenra |
| Genzyme Corporation | $77.46 | 2019-2023 | |
| Covis Pharma Gmbh | $71.73 | 2021-2022 | |
| Insmed, INC. | $69.57 | 2024 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.96 | 2019-2025 | Jascayd |
| Electromed, INC. | $45.15 | 2024 | Smartvest |
| Novartis Pharmaceuticals Corporation | $39.75 | 2019-2022 | |
| Viatris Specialty LLC | $36.60 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $24.40 | 2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $23.99 | 2021 | |
| Genentech USA, INC. | $22.41 | 2025 | Xolair |
| Merck Sharp & Dohme LLC | $22.16 | 2023 | |
| Vifor Pharma, INC. | $22.02 | 2024 | Zemaira |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $20.49 | 2019 | |
| Allergan, INC. | $17.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Lande listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.